Covid-19 Pandemi Döneminde Akciğer Kanseri Yönetimi

Çin’den bütün dünyaya yayılan Covid-19 enfeksiyonu halen dünya genelinde yayılmaya ve ciddi mortalite nede-ni olmaya devam etmektedir. Covid-19 enfeksiyonu sıklıkla ciddi akciğer tutulumuna bağlı pnömoni, ARDS ve solunum yetmezliğiyle mortaliteye neden olmaktadır.Akciğer kanseri hem akciğerdeki lokal direncin düşmesine hem de tedavi süresinde oluşabilen immunsüpresyon ile Covid-19 pnömonisi gibi sekonder enfeksiyonlara bağlı olarak karşı olgularda artmış mortalite riskine neden olmaktadır. Covid-19 enfeksiyonu seyrinde, kanser ve eşlik eden diğer ciddi komorbiditeler; yüksek oranda ağır klinik tablo, yoğun bakım yatışı ve mortaliteye neden olmaktadır. Akciğer kanserli hastaların bireysel olarak değer-lendirilerek, evreleri ve performanslarına göre tedavinin planlanması önerilmektedir. Pandemi sürecinde tanıda endobronşiyal girişimsel tetkikler yerine non-invaziv radyolojik yöntemlerin kullanılması, hastane başvurularının minimuma indirilerek, hastalarda en etkili ancak daha az immunsüpresyon yapan tedavilerin verilmesi planlanmalıdır.

Lung Cancer Management In The Covid-19 Pandemic

Covid-19 infection, spreading from China to the whole world, continues to spread and cause serious mortality.Covid-19 infection causes mortality with pneumonia due to severe lung involvement, ARDS and respiratory failure. Lung cancer causes both a decrease in the local resistance of the lung and an increased risk in cases againstsecondary infections such as Covid-19 pneumonia with immunosuppression that may occur during the treatmentperiod. In the course of Covid-19 infection, cancer and other serious comorbidities cause high rates of severeclinical picture, intensive care admission and mortality. During Covid-19 pandemic, cancer and other serious co-morbidities; It causes high rates of severe clinical picture, intensive care admission and mortality. It is recommended to evaluate patients with lung cancer individually and to plan the treatment according to theirstages and performances. During the pandemic process, it should be planned to use non-invasive radiologicalmethods instead of endobronchial interventional examinations in the diagnosis, to minimize hospital admissionsand to provide the most effective but less immunosuppressive treatments in patients.

PDF

___

1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneu- monia in Wuhan, China: a descriptive study. Lancet 2020;395:507-13. https://doi.org/10.1016/S0140-6736(20)30211-7
2. Zou L, Ruan F, Huang M, et al: SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020;382:1177-9.) https://doi.org/10.1056/NEJMc2001737
3. Rothan HA, Byrareddy SN. The epidemiology and pathoge- nesis of coronavirus disease (Covid-19) outbreak. J. Autoimmun. 26,102433 (2020). https://doi.org/10.1016/j.jaut.2020.102433
4. Liang W, Guan W, Chen R et al. Cancer patients in SARS- CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3),335-7. https://doi.org/10.1016/S1470-2045(20)30096-6
5. Onder G, Rezza G, Brusaferro S: Case-fatality rate and cha- racteristics of patients dying in relation to Covid-19 in Italy . JAMA https://doi.org/10.1001/jama.2020.4683
6. Zhang L, Zhu F, Xie L, et al: Clinical characteristics of Covid- 19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol doi:10.1016/j.annonc.2020.03.296)
7. Calabro L, Peters S, Soria JC, et al: Challenges in lung cancer therapy during the Covid-19 pandemic [epub ahead of print on April 9, 2020]. Lancet Respir Med ‘ doi:10.1016/ S2213-2600(20)30170-3)
8. Wahidi MM, Lamb C, Murgu S, et al: American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory spe- cimen collection in patients with suspected or confirmed Covid-19 infection [epub ahead of print March 18,2020]. J Bronchology Interv Pulmonol doi:10.1097/ LBR.0000000000000681)
9. El-Osta H, Jani P, Mansour A, et al: Endobronchial ultrasound for nodal staging of patients with non-small-cell lung can- cer with radiologically normal mediastinum: A meta-analy- sis. Ann Am Thorac Soc 15:864-74, 2018) https://doi.org/10.1513/AnnalsATS.201711-863OC
10. Deng Q, Fang Q, Sun H, et al: Detection of plasma EGFR mutations for personalized treatment of lung cancer pati- ents without pathologic diagnosis. Cancer Med 9:2085-95, 2020) https://doi.org/10.1002/cam4.2869
11. American College of Surgeons: Covid-19 guidelines for triage of thoracic patients. https://www.facs.org/Covid-19/ clinical-guidance/elective-case/thoraciccancer
12. National Comprehensive Cancer Network Guidelines in Oncology. Non-Small Cell Lung Cancer. https://www. nccn.org/pr ofessionals/physician_gls/Default.aspx. Accessed May 5,2020.
13. Salazar MC, Rosen JE, Wang Z, et al: Association of delayed adjuvant chemotherapy with survival after lung cancer sur- gery. JAMA Oncol 3:610-9,2017 https://doi.org/10.1001/jamaoncol.2016.5829
14. Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung can- cer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6:863-73. https://doi.org/10.1016/S2213-2600(18)30277-7
15. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vino- relbine plus cisplatin as adjuvant treatment for stage II-IIIA. Lancet Oncol. 2018;19:139-148. https://doi.org/10.1016/S1470-2045(17)30729-5
16. Pignon JP, Tribodet H, Scagliotti GV, et al: Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE Collaborative Group. J Clin Oncol 26:3552-9, 2008) https://doi.org/10.1200/JCO.2007.13.9030
17. Lewis J, Gillaspie EA, Osmundson EC, et al: Before or after: Evolving neoadjuvant approaches to locally advanced non- small cell lung cancer. Front Oncol 8:5, https://doi.org/10.3389/fonc.2018.00005
18. Antonia SJ, Villegas A, Daniel D, et al: Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342-50, 2018 https://doi.org/10.1056/NEJMoa1809697
19. Senan S, Brade A, Wang LH, et al: PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:953-62, 2016) https://doi.org/10.1200/JCO.2015.64.8824
20. Hanna N, Neubauer M, Yiannoutsos C, et al: Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inope- rable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755- 60, 2008 https://doi.org/10.1200/JCO.2008.17.7840
21. Aggarwal C, Thompson JC, Black TA, et al: Clinical implica- tions of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung can- cer. JAMA Oncol 5:173-80, 2019 https://doi.org/10.1001/jamaoncol.2018.4305
22. Ettinger DS, Wood DE, Aggarwal C, et al: NCCN guidelines insights: Non-small cell lung cancer, version 1.2020. J Natl Compr Canc Netw 17:1464-72, 2019
23. Bersanelli M. Controversies about Covid-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020;12:269-73.) https://doi.org/10.2217/imt-2020-0067
24. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473. https://doi.org/10.1016/S0140-6736(20)30317-2
25. Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr. Blood Cancer 64,12 (2017). https://doi.org/10.1002/pbc.26642
26. Chen C, Zhang XR, Ju ZY, He WF. Advances in the research of cytokine storm mechanism induced by corona virus dise- ase 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi 36(0), E005 (2020).
27. Xu Z, Shi L, Wang Y et al. Pathological findings of Covid-19 associated with acute respiratory distress syndrome. Lancet Respi. Med. doi:10.1016/S2213-2600(20)30076-X (2020) (Epub ahead of print). https://doi.org/10.1016/S2213-2600(20)30076-X
28. Marina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang et al. Covid-19 in patients with thoracic malignanci- es (TERAVOLT): first results of an international, registry- based, cohort study. Lancet Oncol 2020;21:914-22 https://doi.org/10.1016/S1470-2045(20)30314-4
29. Hurkmans DP, Basak EA, van Dijk T, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer. 2019;7:192. https://doi.org/10.1186/s40425-019-0669-y